Psychiatrists accuse Sepracor of 'misleading' ad campaign

Several high-profile psychiatrists have criticized Sepracor for what they believe are misleading ads for the drug company's new insomnia drug, Lunesta. The psychiatrists say that consumers may be left with an unrealistic impression of just what kind of benefits the drug is likely to provide, including how fast it will take them to go to sleep and their chances for a full night's rest. This new dispute highlights the added attention drug companies are receiving for the claims they make in direct-to-consumer campaigns.

- read this report from the Boston Globe for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.